The detection of other genomic features was also dependent on site-specific signatures, including ALK fusion detection in lung cancer (TCGA-LUSC n = 270, AUROC 0.678 versus 0.404, P < 0.001; TCGA-LUAD n = 231, AUROC 0.637 versus 0.417, P < 0.001) and immune subtype34 detection in half of the cancers analyzed. This evidence concerns the gene ALK and lung cancer.